Trial · NCT00066066

Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers

NCT00066066, Phase 2, Completed, The Forsyth Institute; results first posted 2013-04-22

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers. Trials, record NCT00066066. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00066066

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers
NCT number: NCT00066066
Status: Completed
Phases: Phase 2
Enrollment: 146 participants, actual
Lead sponsor: The Forsyth Institute
Conditions: Periodontitis, Periodontal Diseases
Interventions: Scaling and root planing, Metronidazole, Amoxicillin, Doxycycline
First posted: 2003-08-05
Last updated: 2013-04-22
Results first posted: 2013-04-22

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in Mean Clinical Attachment Level.	Baseline, 3, 6 and 12 months	Periodontal diseases are clinically diagnosed by assessments of gingival inflammation and measurements of tissue destruction. The damage to the apparatus of support of the teeth is quantified using measurements of probing pocket depth (PD) and clinical attachment level (CAL). These measurements are obtained using a periodontal probe which is introduced into the gingival sulcus to determine the distance in millimeters from the gingival margin to the depth of the sulcus or pocket (PD). Since the gingival margin fluctuates in response to inflammation (hyperplasia) or might recede, a more accurate measure of loss of attachment is obtained using the CAL, which measures the distance from a "fixed" landmark on the tooth such as the cemento-enamel junction to the depth of the pocket. Changes in CAL from baseline were used to assess results obtained with the treatment of periodontal diseases.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in Mean Clinical Attachment Level.	Baseline, 3, 6 and 12 months	Of the 146 subjects, 117 were included in the analysis, who had 2 or fewer missing monitoring visits. 84 subjects had complete data, 23 subjects had one missing visit and 10 subjects had 2 missing visits. For the 33 subjects with missing visits, data were carried forward. 68 subjects were non smokers and 49 subjects were current smokers.	mm	MEAN

Source ClinicalTrials.gov

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Change in Mean Clinical Attachment Level.	Scaling and Root Planing Only NonSmokers	Changes in mean CAL from baseline to 3 months	0.11	Standard Error 0.06	mm
Change in Mean Clinical Attachment Level.	SRP Only Smokers	Changes in mean CAL from baseline to 3 months	0.10	Standard Error 0.04	mm
Change in Mean Clinical Attachment Level.	SRP + Metronidazole NonSmokers	Changes in mean CAL from baseline to 3 months	0.21	Standard Error 0.05	mm
Change in Mean Clinical Attachment Level.	SRP + Metronidazole Smokers	Changes in mean CAL from baseline to 3 months	0.08	Standard Error 0.06	mm
Change in Mean Clinical Attachment Level.	SRP + MET + Amoxicillin + Doxycycline NonSmokers	Changes in mean CAL from baseline to 3 months	0.29	Standard Error 0.07	mm
Change in Mean Clinical Attachment Level.	SRP + MET + Amoxicillin + Doxycycline Smokers	Changes in mean CAL from baseline to 3 months	0.28	Standard Error 0.06	mm
Change in Mean Clinical Attachment Level.	Scaling and Root Planing Only NonSmokers	Changes in mean CAL from baseline to 6 months	0.15	Standard Error 0.06	mm
Change in Mean Clinical Attachment Level.	SRP Only Smokers	Changes in mean CAL from baseline to 6 months	0.19	Standard Error 0.05	mm
Change in Mean Clinical Attachment Level.	SRP + Metronidazole NonSmokers	Changes in mean CAL from baseline to 6 months	0.19	Standard Error 0.07	mm
Change in Mean Clinical Attachment Level.	SRP + Metronidazole Smokers	Changes in mean CAL from baseline to 6 months	0.13	Standard Error 0.07	mm

1 to 10 of 18Source ClinicalTrials.gov

See all 18 results by group

Participant flow42

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Scaling and Root Planing (SRP) Only NonSmokers	27
Overall Study	STARTED	SRP Only Smokers	22
Overall Study	STARTED	SRP and Metronidazole (MET) NonSmokers	30
Overall Study	STARTED	SRP and Metronidazole (MET) Smokers	20
Overall Study	STARTED	SRP and Amoxicillin, MET, Local Tetracycline NonSmokers	27
Overall Study	STARTED	SRP and Amoxicillin, MET, Local Tetracycline Smokers	20
Overall Study	Baseline	Scaling and Root Planing (SRP) Only NonSmokers	27
Overall Study	Baseline	SRP Only Smokers	22
Overall Study	Baseline	SRP and Metronidazole (MET) NonSmokers	30
Overall Study	Baseline	SRP and Metronidazole (MET) Smokers	20

1 to 10 of 42Source ClinicalTrials.gov

See all 42 participant flow

Adverse events18

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Gastrointestinal Upset	Gastrointestinal disorders	Scaling and Root Planing (SRP) Only NonSmokers	8	27	8
other	Gastrointestinal Upset	Gastrointestinal disorders	SRP Only Smokers	4	22	4
other	Gastrointestinal Upset	Gastrointestinal disorders	SRP and Metronidazole (MET) NonSmokers	10	30	10
other	Gastrointestinal Upset	Gastrointestinal disorders	SRP and Metronidazole (MET) Smokers	3	20	3
other	Gastrointestinal Upset	Gastrointestinal disorders	SRP and Amoxicillin, MET, Local Tetracycline NonSmokers	6	27	6
other	Gastrointestinal Upset	Gastrointestinal disorders	SRP and Amoxicillin, MET, Local Tetracycline Smokers	5	20	5
serious	hospitalizations	Surgical and medical procedures	Scaling and Root Planing (SRP) Only NonSmokers	1	27	1
serious	hospitalizations	Surgical and medical procedures	SRP Only Smokers	0	22	0
serious	hospitalizations	Surgical and medical procedures	SRP and Metronidazole (MET) NonSmokers	2	30	2
serious	hospitalizations	Surgical and medical procedures	SRP and Metronidazole (MET) Smokers	2	20	2

1 to 10 of 18Source ClinicalTrials.gov

See all 18 adverse events

Adverse event totals18

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Scaling and Root Planing (SRP) Only NonSmokers
Total, all-cause mortality	SRP Only Smokers
Total, all-cause mortality	SRP and Metronidazole (MET) NonSmokers
Total, all-cause mortality	SRP and Metronidazole (MET) Smokers
Total, all-cause mortality	SRP and Amoxicillin, MET, Local Tetracycline NonSmokers
Total, all-cause mortality	SRP and Amoxicillin, MET, Local Tetracycline Smokers
Total, other adverse events	Scaling and Root Planing (SRP) Only NonSmokers	8	27
Total, other adverse events	SRP Only Smokers	4	22
Total, other adverse events	SRP and Metronidazole (MET) NonSmokers	10	30
Total, other adverse events	SRP and Metronidazole (MET) Smokers	3	20

1 to 10 of 18Source ClinicalTrials.gov

See all 18 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
33197289	DERIVED

Source PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01DE014242	Three Periodontal Therapies in Current & Non-Smokers	HAFFAJEE, ANNE DENISE	ADA FORSYTH INSTITUTE, INC.	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH	2003 to 2007

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00066066

GET https://conductscience.org/api/trials/v1/NCT00066066/flow?page=2

API reference For AI assistants